CXCL8 and rheumatoid arthritis: Changes in gene expression with anti-TNF-α therapy were largely similar between patients receiving infliximab and etanercept, with the notable exception of significantly increased expression of the chemokine IL8 in patients on etanercept compared to healthy controls and to RA patients on DMARD or infliximab therapies (Table 3).